Angitia Biopharmaceuticals has closed a $120 million Series C financing round led by Bain Capital Life Sciences with significant participation from new investor Janus Henderson and existing investors. The proceeds will support the development of novel treatments for serious musculoskeletal diseases, including AGA2118, AGA2115, and AGA111.